-

SHAREHOLDER ALERT: Robbins LLP is Investigating CleanSpark, Inc. (CLSK) on Behalf of Shareholders

SAN DIEGO & WOODS CROSS, Utah--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP is investigating CleanSpark, Inc. (NASDAQ: CLSK) to determine whether certain CleanSpark officers and directors violated the Securities Exchange Act of 1934 and breached their fiduciary duties to the Company. CleanSpark provides advanced software and controls technology solutions, including end-to-end microgrid energy modeling, energy market communications, and energy management solutions.

If you suffered a loss due to CleanSpark, Inc.'s misconduct, click here.

CleanSpark, Inc. (CLSK) May Have Misled Investors About its Related Party Transactions and its Customer and Contract Figures

On December 31, 2020, CleanSpark issued a press release touting its achievements and "a number of significant wins for the Company." As for outlook, the Company "forecast[ed] that our second and third fiscal quarters will again be our strongest" and projected it would "generate $20 million in revenue related to our current business segments and we expect the recent acquisition of ATL Data Center to contribute a minimum of $10 million in additional Bitcoin-based (BTC-USD) revenues for 2021."

On January 14, 2021, Culper Research published a report alleging that CleanSpark had "fabricated key elements of its business, including purported customers and contracts" and that it is "rife with undisclosed related party transactions." Specifically, the report alleged that the acquisition of ATL Data Centers, LLC "is another Gutless Promotion Attempt" and that the Company's acquisition of p2k Labs was "an undisclosed related party transaction that apparently fabricated its customers." On this news, the Company's share price fell $3.63, or 9%, to close at $35.71 per share on January 14, 2021. The stock now trades at just around $16.00.

CleanSpark, Inc. (CLSK) Shareholders Have Options

All representation is on a contingency fee basis. Shareholders pay no fees or expenses.

Contact us to learn more:
Lauren Levi
(800) 350-6003
llevi@robbinsllp.com
Shareholder Information Form

Robbins LLP is a nationally recognized leader in shareholder rights law. To be notified if a class action against CleanSpark, Inc. settles or to receive free alerts about corporate executives engaged in wrongdoing, sign up for Stock Watch today.

Attorney Advertising. Past results do not guarantee a similar outcome.

Contacts

Lauren Levi
Robbins LLP
llevi@robbinsllp.com
(800) 350-6003
www.robbinsllp.com

More News From Robbins LLP

Did You Lose Money in Stride, Inc.? Contact Robbins LLP for Information About Your Rights Against LRN.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: The company: Stride, Inc. (NYSE: LRN) is a technology company that provides an education platform to deliver online learning to students throughout the U.S. What is the class period? October 22, 2024 - October 28, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Stride during the class period because the Company allegedly misled investors regarding i...

Did You Lose Money in Perrigo Company? PRGO Stockholders Should Contact Robbins LLP for Information About Their Rights Against PRGO.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Perrigo Company (NYSE: PRGO) provides over-the-counter health and wellness solutions in the U.S., Europe, and internationally. What is the class period? February 27, 2024 - November 4, 2025 What is the Case About? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who acquired Perrigo securities during the class period because the Company allegedly misled investors regarding the value of its infant formula...

Did You Suffer Financial Loss in Skye Bioscience, Inc.? Stockholders Should Contact Robbins LLP for Information About Their Rights Against SKYE.

SAN DIEGO--(BUSINESS WIRE)--Robbins LLP: Company: Skye Bioscience, Inc. (NYSE: SKYE) is a clinical stage biopharmaceutical company that focuses on developing molecules that modulate G protein-coupled receptors (“GPCRs”) to treat obesity, overweight, and metabolic diseases. The Company’s lead product candidate is nimacimab. What is the class period? November 4, 2024 - October 3, 2025 What is the case about? Robbins LLP reminds stockholders that a class action was filed on behalf of all investors...
Back to Newsroom